DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Biotech's"


2 mentions found


☆ Biogen soars 43% after its Alzheimer's drug helps slow down cognitive decline in late-stage study
  + stars: | 2022-09-28 | by ( Matthew Fox | ) www.businessinsider.com   time to read: +3 min
Biogen soared 43% on Wednesday after the company's Alzheimer's drug showed solid results in slowing the cognitive decline of patients. The drug, lecanemab, slowed cognitive decline by 27% after 18 months in a phase three clinical trial. Specifically, the drug helped reduce the pace of cognitive decline in people with early Alzheimer's by 27% over 18 months, compared to a placebo. The drug is separate from Biogen's aduhelm Alzheimer's drug, which was approved by the FDA last year in what was seen as a controversial decision. Biogen's positive Alzheimer's drug results is moving a handful of stocks that are focused on developing therapies in the space.
☆ We went inside the lab at Vertex, a company that dodged the market downturn to become one of the best-performing biotechs of 2022
  + stars: | 2022-09-21 | by ( Andrew Dunn | ) www.businessinsider.com   time to read: +10 min
A mosaic of human cells inside Vertex Pharmaceuticals' cell and gene-therapy laboratory. The four-story, 267,000-square-foot space is home to Vertex's cell and gene-therapy unit, with about 375 people now residing in the modern-industrial building. That has led to going after unrelated diseases like sickle cell, diabetes, muscular dystrophy, kidney disease, and pain. For instance, Vertex's approach to sickle cell is led by its CRISPR gene-editing program. Vertex PharmaceuticalsThe next test of Vertex's strategy will be an experimental treatment called exa-cel, its CRISPR gene-editing program for sickle cell.
<< prev 1 next >>
Total: 2